4.4 Review

Racial Differences in the Cholesterol-Lowering Effect of Statin

期刊

出版社

JAPAN ATHEROSCLEROSIS SOC
DOI: 10.5551/jat.RV16004

关键词

Statin; Racial differences; Asian; Westerner

资金

  1. Takeda Pharmaceutical
  2. Bristol-Myers Squibb
  3. Nippon Boehringer Ingelheim
  4. Astellas Pharma
  5. Novartis Pharma
  6. MSD
  7. Sanofi-Aventis
  8. Otsuka Pharmaceutical
  9. Dainippon Sumitomo Pharma
  10. Pfizer
  11. Kowa Pharmaceutical
  12. Shionogi
  13. AstraZeneca
  14. Teijin
  15. Morinaga Milk Industry

向作者/读者索取更多资源

Statin treatment to reduce low-density lipoprotein cholesterol (LDL-C) is associated with the prevention of cardiovascular events in Western patients. Similar results have been reported in studies conducted in Japan. However, the dose of statins and the degree of LDL-C reduction achieved with statins are different between Asian and Western patients. In addition, there are limited data regarding racial differences in response to statins. In this review, racial differences between Asians and Westerners in response to statins are described.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据